Salud Intestinal & Probiotics:
The New Pillar of Medicine

1. The Human Microbiome: An Ecosystem Within

The human microbiome refers to the collective genome of all micro-organisms — bacteria, archaea, fungi, viruses, and bacteriophages — inhabiting the human body. While microbial communities exist on the skin, in the oral cavity, lungs, and urogenital tract, the gastrointestinal tract hosts the densest and most diverse population, with the colon alone containing roughly 10¹¹ bacteria per gram of luminal content.

The landmark Human Microbiome Project (HMP), launched by the NIH in 2007 and publishing its major findings in 2012, catalogued microbial communities across 242 healthy adults using 16S rRNA gene sequencing and whole-genome shotgun metagenomics. The project revealed that while the species composition varies enormously between individuals, the metabolic pathways encoded by the collective microbiome are remarkably stable — suggesting that functional redundancy rather than taxonomic identity defines a healthy microbiome.

At the phylum level, the healthy adult gut is dominated by Firmicutes (including Lactobacillus, Clostridium, Ruminococcus) and Bacteroidetes (including Bacteroides, Prevotella), which together account for over 90% of bacterial sequences. Smaller but clinically important phyla include Actinobacteria (home to Bifidobacterium), Proteobacteria (which includes potential pathogens like Escherichia coli), and Verrucomicrobia (Akkermansia muciniphila, increasingly recognised for metabolic health).

The microbiome is established at birth — with vaginal delivery providing the initial inoculum from maternal vaginal and faecal flora — and continues to diversify rapidly during the first three years of life. Breastfeeding, antibiotic exposure, diet, geography, and host genetics all shape its maturation. By age three, the microbial community stabilises into an adult-like configuration, though it remains responsive to dietary changes, medications, and environmental shifts throughout life.

2. Dysbiosis and Disease: When the Ecosystem Fails

Dysbiosis is broadly defined as a compositional or functional imbalance in the gut microbial community that disrupts the symbiotic relationship between microbes and host. It is not simply a reduction in "good bacteria" but rather a shift in community structure that compromises the ecosystem's ability to perform essential functions: short-chain fatty acid (SCFA) production, bile acid metabolism, pathogen colonisation resistance, and immune regulation.

Dysbiosis has been implicated in a growing list of conditions spanning virtually every organ system:

• Gastrointestinal: Irritable bowel syndrome (IBS), inflammatory bowel disease (IBD — Crohn's and ulcerative colitis), Clostridioides difficile infection, colorectal cancer
• Metabolic: Obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), metabolic syndrome
• Neuropsychiatric: Depression, anxiety, autism spectrum disorder, Parkinson's disease
• Autoimmune: Rheumatoid arthritis, multiple sclerosis, type 1 diabetes, coeliac disease
• Allergic: Atopic dermatitis, food allergies, asthma

Key drivers of dysbiosis include broad-spectrum antibiotics (which can reduce microbial diversity by 30% within days), proton pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs), ultra-processed diets low in fibre, chronic psychological stress, and excessive alcohol consumption. The Western diet — rich in refined sugars and saturated fats but depleted of fermentable fibres — is now considered one of the most potent promoters of dysbiosis worldwide.

3. Basado en Evidencia Probiotics: Beyond Marketing

The WHO/FAO defines probiotics as "live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host" (2001). This definition carries three critical implications: the organism must be alive at the time of consumption, the dose must be clinically effective (typically ≥ 10⁹ CFU/day), and the benefit must be demonstrated through rigorous clinical trials.

The evidence base for probiotics has expanded enormously over the past two decades. However, the field is plagued by heterogeneity — different strains, doses, durations, and patient populations make meta-analyses challenging. A foundational principle of modern probiotic science is that effects are strain-specific: Lactobacillus rhamnosus GG has different clinical properties from Lactobacillus rhamnosus LR04, even though they belong to the same species.

The strongest levels of evidence (Grade A, supported by multiple randomised controlled trials and meta-analyses) exist for the following indications:

• Antibiotic-associated diarrhoea (AAD): Saccharomyces boulardii and Lactobacillus rhamnosus GG reduce the risk by 40–60% (Cochrane 2017).
• Clostridioides difficile infection prevention: Multi-strain probiotics reduce recurrence risk by ~60% (Goldenberg et al., 2017).
• Acute infectious diarrhoea in children: L. rhamnosus GG and S. boulardii reduce duration by approximately 1 day (Szajewska et al., 2020).
• Necrotising enterocolitis (NEC) in preterm neonates: Multi-strain probiotics reduce NEC incidence and all-cause mortality (Cochrane 2020).
• IBS symptom management: Bifidobacterium infantis 35624 and multi-strain formulations improve global symptoms and bloating.

4. Specific Strains and Their Clinical Indications

Choosing the right probiotic requires matching the specific strain to the clinical indication, at the correct dose, for an appropriate duration. The table below summarises key evidence-based strain–indication pairs:

It is essential to note that probiotic supplements are not interchangeable. Commercial products containing unspecified "Lactobacillus blend" at undisclosed doses lack the evidence to support specific health claims. Clinicians should recommend products that identify strains by their full designation (genus, species, and strain code) and that provide third-party verification of viability at expiration — not merely at the time of manufacture.

5. Prebiotics and Synbiotics: Feeding the Good Bacteria

Prebiotics are defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as "a substrate that is selectively utilised by host micro-organisms conferring a health benefit" (Gibson et al., 2017). In practical terms, these are mostly non-digestible dietary fibres that pass intact through the upper GI tract and are fermented by colonic bacteria into beneficial metabolites — chiefly short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate.

The most well-studied prebiotics include:

• Inulin and fructo-oligosaccharides (FOS): Found naturally in chicory root, garlic, onions, leeks, asparagus, and bananas. Selectively promote Bifidobacterium growth. Effective dose: 5–10 g/day.
• Galacto-oligosaccharides (GOS): Found in legumes and produced commercially from lactose. Particularly effective in infant formulas to mimic the bifidogenic effect of human milk oligosaccharides (HMOs).
• Resistant starch: Found in cooked-then-cooled potatoes, green bananas, and legumes. Fermented primarily to butyrate, which serves as the main energy source for colonocytes and has anti-inflammatory properties.
• Pectin: Found in apples, citrus fruits, and berries. Supports a diverse microbial community and SCFA production.

Synbiotics combine a probiotic and a prebiotic in a single formulation. They can be "complementary" (the prebiotic feeds general beneficial microbes) or "synergistic" (the prebiotic specifically supports the co-administered probiotic strain). A well-known example is the combination of Bifidobacterium strains with FOS, where the FOS specifically enhances the survival and colonisation of the administered Bifidobacterium.

6. The Gut-Brain Axis: Your Second Brain

The gut-brain axis refers to the bidirectional communication network linking the enteric nervous system (ENS) — sometimes called the "second brain" — with the central nervous system (CNS). This axis operates through four principal channels: the vagus nerve (the primary neural highway), the hypothalamic-pituitary-adrenal (HPA) axis, the immune system (via cytokines), and microbial metabolites (SCFAs, tryptophan derivatives, and neurotransmitters).

Remarkably, the gut produces approximately 95% of the body's serotonin and significant quantities of dopamine, GABA, and norepinephrine. While most of this serotonin functions locally (regulating motility, secretion, and visceral sensation), microbial metabolites influence central serotonin signalling through vagal afferents and circulating tryptophan precursors.

Preclinical studies have demonstrated dramatic effects of the microbiome on brain and behaviour. Germ-free mice exhibit exaggerated HPA axis responses to stress, altered anxiety-like behaviours, and changes in hippocampal BDNF expression — all of which can be partially reversed by colonisation with specific bacterial strains (Sudo et al., 2004). Lactobacillus rhamnosus JB-1 administration in mice reduced anxiety and depression-like behaviours and altered GABA receptor expression in the brain, with effects abolished by vagotomy (Bravo et al., 2011).

In humans, the evidence is still emerging but promising. A randomised controlled trial by Tillisch et al. (2013) showed that a four-week multi-strain probiotic intervention altered brain activity patterns in regions controlling emotion processing, as measured by functional MRI. The concept of "psychobiotics" — live organisms that, when ingested in adequate amounts, produce a health benefit in patients suffering from psychiatric illness — was formalised by Dinan et al. in 2013 and has since become a rapidly growing research field.

7. Diet for Salud Intestinal: Practical Strategies

No single food or supplement can build a healthy microbiome — it requires a consistently diverse, fibre-rich dietary pattern. The American Gut Project, which analysed over 10,000 faecal samples, found that the single strongest predictor of a diverse and healthy microbiome was the number of different plant species consumed per week. Individuals eating 30 or more plant types per week had significantly greater microbial diversity than those consuming fewer than 10.

Evidence-based dietary strategies for optimal gut health include:

• Aim for 30+ plant varieties per week: This includes vegetables, fruits, whole grains, legumes, nuts, seeds, herbs, and spices. Each provides unique fibres and polyphenols that feed different microbial species.
• Consume 25–35 g of dietary fibre daily: Most Western populations average only 15 g/day. Increase gradually (by 5 g/week) to minimise bloating. Prioritise diverse fibre sources over isolated supplements.
• Include fermented foods daily: Yoghurt (with live cultures), kefir, sauerkraut, kimchi, miso, tempeh, and kombucha introduce live microbes and bioactive metabolites. A Stanford study (Sonnenburg et al., 2021) showed that a high-fermented-food diet increased microbial diversity and reduced inflammatory markers more than a high-fibre diet alone over 10 weeks.
• Eat polyphenol-rich foods: Dark berries, green tea, extra-virgin olive oil, dark chocolate, and red wine (in moderation) contain polyphenols that act as prebiotics, selectively promoting Akkermansia and Bifidobacterium.
• Limit ultra-processed foods: Emulsifiers (carboxymethylcellulose, polysorbate 80), artificial sweeteners (saccharin, sucralose), and excess refined sugar disrupt mucus layer integrity and promote pro-inflammatory bacterial species.
• Maintain regular meal timing: The microbiome has circadian rhythms. Irregular eating patterns disrupt microbial oscillations and impair metabolic function.

The Mediterranean Diet: A Microbiome Champion

The Mediterranean diet — characterised by abundant vegetables, fruits, legumes, whole grains, nuts, olive oil, and moderate fish and fermented dairy — consistently ranks as the most gut-friendly dietary pattern in clinical research. The NU-AGE trial demonstrated that one year of Mediterranean diet adherence in elderly Europeans reshaped the gut microbiome in ways associated with reduced frailty, improved cognitive function, and lower systemic inflammation. Specifically, it increased taxa associated with SCFA production (Faecalibacterium prausnitzii, Roseburia) and decreased pro-inflammatory species.

8. When to Supplement: Clinical Decision-Making

Not everyone needs a probiotic supplement. The decision to recommend probiotics should be guided by specific clinical indications, strain-level evidence, and patient characteristics. Probiotics are most clearly beneficial in the following scenarios:

• During and after antibiotic therapy: To prevent antibiotic-associated diarrhoea. Begin concurrently with the antibiotic (spaced 2 hours apart) and continue for at least 1 week after the course ends.
• Recurrent C. difficile infection: As adjunctive therapy alongside standard antibiotic treatment (vancomycin or fidaxomicin).
• IBS with predominant bloating or diarrhoea: Strain-specific probiotics (B. infantis 35624, multi-strain formulations) for a minimum 4-week trial.
• Preterm infants at risk of NEC: Multi-strain probiotics administered under neonatal unit protocols.
• Traveller's diarrhoea prevention: S. boulardii or L. rhamnosus GG starting 5 days before travel.

Probiotics are generally safe in immunocompetent individuals, with bloating and flatulence being the most common side effects (usually self-limiting within 2–3 days). However, caution is warranted in severely immunocompromised patients (transplant recipients, those on chemotherapy, severe acute pancreatitis), where rare cases of bacteraemia and fungaemia from probiotic organisms have been reported.

The future of gut health medicine lies in precision approaches — personalised microbiome therapies tailored to an individual's unique microbial signature. Faecal microbiota transplantation (FMT), already the standard of care for recurrent C. difficile infection (with cure rates exceeding 90%), is being investigated for IBD, metabolic syndrome, and even neurological conditions. Next-generation probiotics, including genetically engineered strains and live biotherapeutic products (LBPs) like Akkermansia muciniphila, are currently in phase II/III clinical trials and may redefine how we treat chronic disease in the coming decade.